Celgene and BeiGene Ltd collaborate to licence BGB A317 an advanced PD I inhibitor to Celgene and to licence certain Celgene products to BeiGene in China.

Celgene Corporation and BeiGene, Ltd. entered into a strategic collaboration to develop and commercialize BeiGene's investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB A317, for patients with solid tumor cancers in the United States, Europe, Japan and rest of world outside Asia. BeiGene will retain exclusive rights for the development and commercialization of BGB A317 for hematological malignancies globally and for solid tumors in Asia (with the exception of Japan). BeiGene will acquire Celgene's commercial operations in China and gain an exclusive license to commercialize Celgene's approved therapies in China - Abraxane, Revlimid and Vidaza.

BGB A317 is an advanced clinical-stage investigational PD-1 inhibitor, which has been dosed in over 500 patients. Initial clinical data suggest that BGB A317 is well tolerated and exhibits anti-tumor activity across a range of solid tumor types. BGB A317 has high affinity and specificity for PD-1 and may be differentiated from the currently approved PD-1 antibodies through an engineered Fc region, potentially minimizing interactions with other immune cells that may exert a negative impacctor T-cell function. BGB A317 is being developed as a monotherapy and in combination with other therapies for the treatment of solid tumor cancers. It is currently in two pivotal trials in China, and global pivotal studies of BGB A317 are planned for initiation in 2018. Celgene and BeiGene will collaborate in the global development of BGB A317. In addition, BeiGene retains the right to develop BGB A317 in hematology and in combination with its other portfolio compounds.

In addition, BeiGene is granted licensing rights in China to CC-122, under the same terms and conditions as the approved commercial products. CC-122 is a next generation CelMOD currently in development by Celgene for lymphoma and hepatocellular carcinoma. BeiGene plans to expand manufacturing and commercial operations in China in preparation for the potential approvals of BGB A317 and future innovative therapies developed by BeiGene in greater China. .